C4 Therapeutics Stock Analysis

CCCC Stock Analysis Notes

About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. C4 Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 1.52. The firm had not issued any dividends in recent years. C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people. For more info on C4 Therapeutics please contact Andrew MBA at 617 231 0700 or go to https://www.c4therapeutics.com.

C4 Therapeutics Investment Alerts

C4 Therapeutics Upcoming and Recent Events

CCCC Largest EPS Surprises

View All Earnings Estimates

C4 Therapeutics Environmental, Social, and Governance (ESG) Scores

CCCC Stock Institutional Investors

Note, although C4 Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

CCCC Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 150.5 M.

CCCC Profitablity

The company has Profit Margin (PM) of (2.96) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.28) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.28.

Management Efficiency

C4 Therapeutics has return on total asset (ROA) of (0.2017) % which means that it has lost $0.2017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4558) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, C4 Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 274 M, whereas Net Tangible Assets are forecasted to decline to about 168.9 M.

Technical Drivers

As of the 23rd of March, C4 Therapeutics owns the Information Ratio of (0.23), market risk adjusted performance of (0.38), and Variance of 17.7. C4 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices.

C4 Therapeutics Price Movement Analysis

C4 Therapeutics Insider Trading Activities

C4 Therapeutics Outstanding Bonds

C4 Therapeutics Predictive Daily Indicators

C4 Therapeutics Corporate Filings

C4 Therapeutics Forecast Models

C4 Therapeutics' time-series forecasting models are one of many C4 Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary C4 Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how C4 Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CCCC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as C4 Therapeutics. By using and applying CCCC Stock analysis, traders can create a robust methodology for identifying CCCC entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. CCCC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. CCCC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

C4 Therapeutics stock analysis indicators help investors evaluate how C4 Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading C4 Therapeutics shares will generate the highest return on investment. By understating and applying C4 Therapeutics stock analysis, traders can identify C4 Therapeutics position entry and exit signals to maximize returns.

When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.